PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial. Li F, Qu L, Liu Y, Wu X, et al. J Hepatol 2025;82:211-221.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li F, Qu L, Liu Y, Wu X, et al. PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial. J Hepatol 2025;82:211-221.
PMID: 39094743